Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia

Oncogene

Volumn 34, Issue 6, 2015, Pages 726-740

  Ma, H ^a   Zhou, H ^a   Song, X ^b   Shi, S ^a   Zhang, J ^a,c   Jia, L ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TROMSØ   (Norway)

^c DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ELAFIN; HAEMATOSIDE SYNTHETASE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; N ACETYLNEURAMINIC ACID; ONCOPROTEIN; PI3 PROTEIN, HUMAN; SIALYLTRANSFERASE; ST8SIA4 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; BIOSYNTHESIS; CHILD; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HL 60 CELL LINE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIDRUG RESISTANCE; PATHOLOGY; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ELAFIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; N-ACETYLNEURAMINIC ACID; ONCOGENE PROTEIN V-AKT; P-GLYCOPROTEIN; SIALYLTRANSFERASES; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84893743919     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.7     Document Type: Article

References (44)

1. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006; 107: 2099-2107.
2. Vander Kolk DM, de Vries EG, Müller M, Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 2002; 43: 685-701.
3. Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis G, Papageorgiou T et al. Expression of multidrug resistance 1 (mdr1), multidrug resistance-related protein 1 (mrp1), lung resistance protein (lrp), and breast cancer resistance protein (bcrp) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 2007; 86: 166-173.
4. Nakano M, Saldanha R, Göbel A, Kavallaris M, Packer NH. Identification of glycan structure alterations on cell membrane proteins in desoxyepothilone B resistant leukemia cells. Mol Cell Proteomics 2011; 10: M111.009001.
5. Zhang Z, Zhao Y, Jiang L, Miao X, Zhou H, Jia L. Glycomic alterations are associated with multidrug resistance in human leukemia. Int J Biochem Cell Biol 2012; 44: 1244-1253.
6. Miyagi T, Wada T, Yamaguchi K, Hata K. Sialidase and malignancy: a minireview. Glycoconj. J 2004; 20: 189-198.
7. Varki N, Varki A. Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest 2007; 87: 851-857.
8. Kim YJ, Kim KS, Kim SH, Kim CH, Ko JH, Choe IS et al. Molecular cloning and expression of human Gal beta 1,3GalNAc alpha 2,3-sialytransferase (hST3Gal II). Biochem Biophys Res Commun 1996; 228: 324-327.
9. Pérez-Garay M, Arteta B, Pagès L, De Llorens R, De Bolòs C, Vidal-Vanaclocha F et al. Alpha2, 3-Sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo. PLoS One 2010; 5: e12524.
10. Recchi M, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res 1998; 58: 4066-4070.
11. Hebbar M, Krzewinski-Recchi M, Hornez L, Verdiere A, Harduin-Lepers A, Bonneterre J. Prognostic value of tumoral sialyltransferase expression and circulating E-selectin concentrations in node-negative breast cancer patients. Int J Biol Markers 2003; 18: 116-122.
12. Susmita M, Sarmila C, Chitra M. Elevated mRNA level of hST6Gal I and hST3Gal V positively correlates with the high risk of pediatric acute leukemia. Leukemia Res 2010; 34: 463-470.
13. Su H, Travis W, Mi-Ran C, Ahmad R. Human b-galactoside aipha-2, 3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity. Mol Cell Biochem 2009; 331: 81-88.
14. Sewell R, Bäckström M, Dalziel M, Gschmeissner S, Karlsson H, Noll T et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem 2006; 281: 3586-3594.
15. Yamada K, Mitsui Y, Kakoi N, Kinoshita M, Hayakawa T, Kakehi K. One-pot characterization of cancer cells by the analysis of mucin-type glycans and glycosaminoglycan. Anal Biochem 2012; 421: 595-606.
16. Martersteck C, Kedersha N, Drapp D, Tsui T, Colley K. Unique alpha 2,8-polysialylated glycoproteins in breast cancer and leukemia cells. Glycobiology 1996; 6: 289-301.
17. Bellacosa A, Kumar C, Di C, Testa J. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29-86.
18. Garcia M, Alaniz L, Russo R, Alvarez E, Hajos S. PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leukemia Res 2009; 33: 288-296.
19. Cordo R, García M, Alaniz L, Blanco G, Alvarez E, Hajos S. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer 2008; 122: 1012-1018.
20. Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, Miyamura T et al. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-pecursor acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 59: 83-89.
21. Parasrampuria R, Mehvar R. Divergent effects of nitric oxide donors on the biliary efflux transporters in isolated perfused rat livers: nitric oxideindependent inhibition of ABC transporters by sodium nitroprusside. Drug Metab Lett 2011; 5: 64-72.
22. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006; 312: 212-217.
23. Ishihara T, Fukuda I, Morita A, Takinami Y, Okamoto H, Nishimura SI et al. Development of quantitative plasma N-glycoproteomics using label-free 2-D LC-MALDI MS and its applicability for biomarker discovery in hepatocellular carcinoma. J Proteomics 2011; 74: 2159-2168.
24. Harvey DJ. Proteomic analysis of glycosylation: structural determination of N-and O-linked glycans by mass spectrometry. Expert Rev Proteomics 2005; 2: 87-101.
25. Zhu Y, Srivatana U, Ullah A, Gagneja H, Berenson CS, Lance P. Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim Biophys Acta 2001; 1536: 148-160.
26. Schauer R. Achievements and challenges of sialic acid research. Glycoconj J 2000; 17: 485-499.
27. Yu S, Wang Q, Zhang J, Wu Q, Guo Z. Synthesis and evaluation of protein conjugates of GM3 derivatives carrying modified sialic acids as highly immunogenic cancer vaccine candidates. Medchemcomm 2011; 2: 524-530.
28. Nakayama J, Suzuki M, Suzuki M, Fukuda M. Expression profiling of glycosyltransferases and related enzymes using in situ hybridization. Methods Enzymol 2006; 416: 120-129.
29. Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 1993; 3: 97-130.
30. Dwek RA. Glycobiology: toward understanding the function of sugars. Chem Rev 1996; 96: 683-720.
31. Tang W, Chang SB, Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell 2004; 15: 4043-4050.
32. Martelli A, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006; 20: 911-928.
33. Billottet C, Banerjee L, Vanhaesebroeck B, Khwaja A. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting ATRA-induced differentiation. Cancer Res 2009; 69: 1027-1034.
34. Abdul-Ghani R, Serra V, Gyorffy B, Jurchott K, Solf A, Dietel M et al. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 2006; 25: 1743-1752.
35. Dobbin Z, Landen C. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci 2013; 14: 8213-8227.
36. García MG, Alaniz LD, Cordo Russo RI, Alvarez E, Hajos SE. PI3K/Akt inhibition modulates multidrug resistance and activates NF-kB in murine lymphoma cell lines. Leukemia Res 2009; 33: 288-296.
37. Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M et al. Differential Effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLoS One 2013; 8: e80070.
38. Wang X, Sun P, Paller A. Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites. J Biol Chem 2003; 278: 48770-48778.
39. Mirkin B, Clark S, Zhang C. Inhibition of human neuroblastoma cell proliferation and EGF receptor phosphorylation by gangliosides GM1, GM3, GD1A and GT1B. Cell Prolif 2002; 35: 105-115.
40. Neiiendam J, Boding K, Christensen C, Li S, Volmer P, Kornerup D et al. An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons. J Neurochem 2004; 91: 920-935.
41. Tazzari P, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007; 21: 427-438.
42. Abdul-Ghani R, Serra V, Györffy B, Jürchott K, Solf A, Dietel M et al. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 2006; 25: 1743-1752.
43. Barancík M, Bohácová V, Sedlák J, Sulová Z, Breier A. LY294002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2006; 29: 426-434.
44. Zhou H, Ma H, Wei W, Ji D, Song X, Jia L. B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1. Cell Death and Disease 2013; 4: e654.